Recursion PHARMACEUTICALS, Inc. (RXRX) intrinsic value & 10-year financials
Recursion PHARMACEUTICALS, Inc. (RXRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 78.4% a year to $74.7M, with an average return on invested capital of -269.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.46
- Market cap
- $1.6B
- Revenue (FY2025)
- $74.7M
- Revenue growth (8-yr CAGR)
- 78.4%
- ROIC (10-yr avg)
- -269.1%
- Free cash flow (FY2025)
- -$378.3M
RXRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $74.7M | -$644.8M | -$1.44 | -$378.3M | -867.9% | -151.3% |
| FY2024 | $58.8M | -$463.7M | -$1.69 | -$372.9M | -814.1% | -179.5% |
| FY2023 | $44.6M | -$328.1M | -$1.58 | -$299.7M | -785.3% | -1282.6% |
| FY2022 | $39.8M | -$239.5M | -$1.36 | -$120.6M | -616.7% | -205.1% |
| FY2021 | $10.2M | -$186.5M | -$1.49 | -$198.4M | -1795.8% | 185.3% |
| FY2020 | $4.0M | -$87.0M | -$0.67 | -$51.2M | -2135.7% | 18.6% |
| FY2019 | $2.3M | -$61.9M | -$0.48 | -$61.0M | -2692.6% | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RECURSION PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
RECURSION PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just 0.4% ROIC.
RECURSION PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, RECURSION PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-47.83 per share.